Prelude Therapeutics Ownership | Who Owns Prelude Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Prelude Therapeutics Ownership Summary

Prelude Therapeutics is owned by 2.11% institutional investors, 13.80% insiders, and 84.10% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.18% of PRLD shares. Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund, with 1.90% of its assets in Prelude Therapeutics shares.

PRLD Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Prelude Therapeutics	2.11%	13.80%	84.10%
Sector	Healthcare Stocks	50.47%	12.28%	37.25%
Industry	Biotech Stocks	49.08%	12.05%	38.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Orbimed advisors	10.91M	14.18%	$37.31M
Baker bros. advisors lp	10.12M	13.16%	$34.62M
Boxer capital	2.57M	3.39%	$9.79M
Kynam capital management, lp	1.59M	2.07%	$5.45M
Vanguard group	1.41M	1.86%	$4.10M
Blackrock	1.07M	1.41%	$4.07M
Two sigma investments, lp	923.63K	1.20%	$3.16M
Sphera funds management	558.34K	0.73%	$1.91M
Acadian asset management	511.52K	0.66%	$1.75M
Millennium management	382.74K	0.50%	$1.31M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Orbimed advisors	10.91M	0.74%	$37.31M
Boxer capital	2.57M	0.52%	$9.79M
Kynam capital management, lp	1.59M	0.34%	$5.45M
Sphera funds management	558.34K	0.30%	$1.91M
Baker bros. advisors lp	10.12M	0.20%	$34.62M
Shay capital	100.00K	0.01%	$144.00K
Bridgeway capital management	53.50K	0.00%	$182.97K
Acadian asset management	511.52K	0.00%	$1.75M
Two sigma investments, lp	923.63K	0.00%	$3.16M
Renaissance	275.20K	0.00%	$941.18K

Top Buyers

Holder	Shares	% Assets	Change
Kynam capital management, lp	1.59M	0.34%	803.68K
Sphera funds management	558.34K	0.30%	435.59K
Vanguard group	1.41M	0.00%	421.13K
Millennium management	382.74K	0.00%	231.74K
Vanguard fiduciary trust	157.38K	0.00%	157.38K

Top Sellers

Holder	Shares	% Assets	Change
Deerfield management company, l.p. (series c)	-	-	-3.77M
Ecor1 capital	-	-	-947.05K
Exoduspoint capital management, lp	-	-	-921.62K
Avidity partners management lp	-	-	-890.00K
Price t rowe associates inc /md/	-	-	-755.96K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	157.38K	0.00%	157.38K	$538.24K
Citadel advisors	124.38K	0.00%	124.38K	$425.37K
Dimensional fund advisors lp	35.21K	-	35.21K	$119.69K
Aqr capital management	12.49K	-	12.49K	$15.93K
Graham capital management	11.34K	0.00%	11.34K	$38.79K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-1.00
Ifp advisors	-1.00
Capital performance advisors llp	-8.00
True wealth design	-13.00
Srs capital advisors	-15.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	13	-73.47%	1,621,555	-94.30%	2	0.15%	8	-66.67%	2	-86.67%
Dec 31, 2025	26	-42.22%	4,054,360	-85.07%	5	0.42%	12	-20.00%	9	-52.63%
Sep 30, 2025	44	-2.22%	27,161,948	1.82%	35	2.90%	15	-11.76%	18	-14.29%
Jun 30, 2025	49	-14.04%	27,188,001	-4.17%	35	2.57%	19	-9.52%	23	-4.17%
Mar 31, 2025	57	-6.56%	30,474,260	-5.26%	40	2.23%	22	-35.29%	24	118.18%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Morn Total Stk Mkt Idx Investor	1.51M	1.90%	577.82K
Vanguard Total Stock Mkt Idx Inv	1.51M	1.90%	577.82K
Vanguard US Total Market Shares ETF	720.43K	1.31%	-
T. Rowe Price Health Sciences	516.22K	0.82%	-40.53K
iShares Russell 2000 ETF	643.71K	0.81%	-11.42K
MFS New Discovery I	327.70K	0.60%	-
Vanguard Institutional Extnd Mkt Idx Tr	458.36K	0.58%	182.38K
Biotech Growth Ord	346.50K	0.44%	-
iShares Russell 2000 Growth ETF	254.41K	0.32%	-2.33K
T. Rowe Price Small-Cap Value	168.61K	0.31%	-90.00

Recent Insider Transactions

Date	Name	Activity	Value
Apr 21, 2026	Bonita David P	Buy	$7.50M
Apr 21, 2026	Bonita David P	Buy	$5.00M
Apr 21, 2026	ORBIMED ADVISORS LLC	Buy	$5.00M
Apr 21, 2026	ORBIMED ADVISORS LLC	Buy	$7.50M
Apr 21, 2026	BAKER BROS. ADVISORS LP	Buy	$213.77

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	6	-
2026 Q1	-	-
2025 Q4	-	-
2025 Q3	-	-
2025 Q2	-	-

PRLD Ownership FAQ

Who Owns Prelude Therapeutics?

Prelude Therapeutics shareholders are primarily institutional investors at 2.11%, followed by 13.80% insiders and 84.09% retail investors. The average institutional ownership in Prelude Therapeutics's industry, Biotech Stocks , is 49.08%, which Prelude Therapeutics falls below.

Who owns the most shares of Prelude Therapeutics?

Prelude Therapeutics’s largest shareholders are Orbimed advisors (10.91M shares, 14.18%), Baker bros. advisors lp (10.12M shares, 13.16%), and Boxer capital (2.57M shares, 3.39%). Together, they hold 30.72% of Prelude Therapeutics’s total shares outstanding.

Does Blackrock own Prelude Therapeutics?

Yes, BlackRock owns 1.41% of Prelude Therapeutics, totaling 1.07M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 4.07M$. In the last quarter, BlackRock decreased its holdings by -28.558K shares, a -2.60% change.

Who is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested?

Orbimed advisors is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.74% of its assets in 10.91M Prelude Therapeutics shares, valued at 37.31M$.

Who is the top mutual fund holder of Prelude Therapeutics shares?

Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund holder of Prelude Therapeutics shares, with 1.90% of its total shares outstanding invested in 1.51M Prelude Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools